NEUROCRINE BIOSCIENCES, INC.
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT01910480
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 102
- Registration Number
- NCT01733121
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 109
- Registration Number
- NCT01688037
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 37
- Registration Number
- NCT01393600
- Locations
- 🇺🇸
Woodland International Research Group, Inc, Little Rock, Arkansas, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Synergy Clinical Research, National City, California, United States
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 10
- Registration Number
- NCT01267188
A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 188
- Registration Number
- NCT00873561
- Locations
- 🇨🇿
University Hospital and School of Medicine, Olomouc, Czech Republic
🇨🇿Faculty Hospital Motol, Prague, Czech Republic
🇫🇮Helsinki University Hospital, Helsinki, Finland
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
- Conditions
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Neurocrine Biosciences
- Registration Number
- NCT00525941
- Locations
- 🇺🇸
Sleep Disorders Center of Georgia, Atlanta, Georgia, United States
🇺🇸Clinilabs, Inc., New York, New York, United States
🇺🇸Tri-State Sleep Disorders Center, Cincinnati, Ohio, United States
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 380
- Registration Number
- NCT00232167
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2008-03-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 150
- Registration Number
- NCT00079495
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Neurocrine Biosciences
- Registration Number
- NCT00014677
- Locations
- 🇺🇸
Charlotte Neurosurgical Associates, Charlotte, North Carolina, United States
🇺🇸UCSD Thornton Hospital, La Jolla, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States